HCV NS-3 serine protease inhibitors

Details HCV NS-3 serine protease inhibitors HCV NS-3 serine protease inhibitors

2005-01-28

2009-10-27

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S010100, C514S019300, C530S331000, C544S141000, C544S372000, C546S208000

Reexamination Certificate

active

07608590

ABSTRACT:
Compounds of the formulawhere the variables are as defined in the specification inhibit the NS3 protease of flavivirus such as hepatitis C virus (HCV). The compounds comprise a novel linkage between a heterocyclic P2 unit and those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.

REFERENCES:
patent: 6265380 (2001-07-01), Tung et al.
patent: 7125845 (2006-10-01), Wu et al.
patent: 2003/0186895 (2003-10-01), Llinas-Brunet et al.
patent: 2004/0048802 (2004-03-01), Ripka et al.
patent: 0 126 587 (1984-11-01), None
patent: 0 443 132 (1991-08-01), None
patent: 1 090 997 (2001-04-01), None
patent: 1 408 031 (2004-04-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO00/47561 (2000-08-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO01/74768 (2001-10-01), None
patent: WO02/08198 (2002-01-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO03/035060 (2003-05-01), None
patent: WO 03/053349 (2003-07-01), None
patent: WO03/062228 (2003-07-01), None
patent: WO03/062265 (2003-07-01), None
patent: WO 03/064416 (2003-08-01), None
patent: WO 03/064455 (2003-08-01), None
patent: WO 03/064456 (2003-08-01), None
patent: WO 03/066103 (2003-08-01), None
patent: WO03/087092 (2003-10-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO 03/099316 (2003-12-01), None
patent: WO 2004/009121 (2004-01-01), None
patent: WO2004/026896 (2004-04-01), None
patent: WO 2004/032827 (2004-04-01), None
patent: WO 2004/037855 (2004-05-01), None
patent: WO2004/039833 (2004-05-01), None
patent: WO 2004/039970 (2004-05-01), None
patent: WO 2004/043339 (2004-05-01), None
patent: WO 2004/072243 (2004-08-01), None
patent: WO2004/092161 (2004-10-01), None
patent: WO2004/093798 (2004-11-01), None
patent: WO 2004/093915 (2004-11-01), None
patent: WO 2004/094452 (2004-11-01), None
patent: WO 2004/101602 (2004-11-01), None
patent: WO 2004/103996 (2004-12-01), None
patent: WO2004/113365 (2004-12-01), None
patent: WO 2005/010029 (2005-02-01), None
patent: WO2005/073195 (2005-08-01), None
patent: WO 2005/073216 (2005-08-01), None
patent: WO2007/014918 (2007-02-01), None
patent: WO2007/014919 (2007-02-01), None
patent: WO2007/014920 (2007-02-01), None
patent: WO2007/014921 (2007-02-01), None
patent: WO2007/014922 (2007-02-01), None
patent: WO2007/014923 (2007-02-01), None
patent: WO2007/014924 (2007-02-01), None
patent: WO2007/014925 (2007-02-01), None
patent: WO2007/014927 (2007-02-01), None
patent: WO2007/017144 (2007-02-01), None
NPL-Flavivirus from www.medterms.com/script/main/art.asp?articlekey=6502, Accessed on Feb. 26, 2008.
NPL-Dengue from www.medterms.com/script/main/art.asp?articlekey=6625, Accessed on Feb. 26, 2008.
NPL-Encephalitis from www.medterms.com/script/main/art.asp?articlekey=3231, Accessed on Feb. 26, 2008.
Zanotti, Giancarlo, et al, “Synthesis of analogues of amaninamide, an amatoxin from the whiteAmanita virosamushroom”,Int. J. Peptide Protein Res: 450-459 (1987).
U.S. Appl. No. 10/572,349, filed Mar. 17, 2006.
U.S. Appl. No. 11/632,102, filed Jan. 10, 2007.
Zanotti, et al, “Synthesis of Ile3-Amaninamide and its Diastereoisomeric (S)-Sulfoxide from the Analogs of Amanin”, (Feb. 25, 1981), Int J. Peptide Protein Res, 18; 1981, pp. 162-168; Munksgaard, Copenhagen, Denmark.

Affiliated with

Also associated with

Rating

HCV NS-3 serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HCV NS-3 serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV NS-3 serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4070220